Efruxifermin Explained
Legal Status: | Investigational |
Synonyms: | AKR-001; AMG-876 |
Cas Number: | 2375240-92-7 |
Unii: | C1KR8TZ3NE |
Pubchemsubstance: | 472421610 |
Efruxifermin (AKR-001) is a fibroblast growth factor 21 (FGF21) analog developed to treat nonalcoholic steatohepatitis and type 2 diabetes.[1] [2] [3]
Notes and References
- Shao . Weijuan . Jin . Tianru . Hepatic hormone FGF21 and its analogues in clinical trials . Chronic Diseases and Translational Medicine . March 2022 . 8 . 1 . 19–25 . 10.1016/j.cdtm.2021.08.005 . 35620160 . en . 2589-0514. 9126297 .
- Carvalho . Thiago . Efruxifermin combined with a GLP-1 receptor agonist reduces liver fat in NASH . Nature Medicine . 20 June 2023 . 29 . 8 . 1881 . 10.1038/d41591-023-00055-1 . 37340082 . 259210572 . en.
- Kaufman . Allegra . Abuqayyas . Lubna . Denney . William S. . Tillman . Erik J. . Rolph . Tim . AKR-001, an Fc-FGF21 Analog, Showed Sustained Pharmacodynamic Effects on Insulin Sensitivity and Lipid Metabolism in Type 2 Diabetes Patients . Cell Reports Medicine . July 2020 . 1 . 4 . 100057 . 10.1016/j.xcrm.2020.100057. free . 33205064 . 7659583 .